Seattle, WA, United States of America

Presage Biosciences, Inc.


USPTO Granted Patents = 5


Trademarks = 1

Forward Citations = 7

Loading Chart...
Loading Chart...

7 inventors (with patents filed for the assignee):

goldMedal Richard Klinghoffer (4 out of 6 patents)

silverMedal Joyoti Dey (3 out of 3 patents)

bronzeMedal Jason Frazier (1 out of 1 patent)

4.  Marc Grenley (1 out of 1 patent)

5.  Mandana Veiseh (1 out of 21 patents)

6.  S Bahram Bahrami (1 out of 9 patents)

7.  James M Olson (1 out of 18 patents)


5 patents:

Company Overview
Presage Biosciences, Inc. is a biotechnology company dedicated to revolutionizing cancer treatment. By utilizing their proprietary 3D tissue microarray technology, they provide significant advancements in precision medicine. Their innovative approach allows for the simultaneous delivery and assessment of multiple therapies directly within intact tumors, enabling tailored therapeutic strategies. The company's mission is to empower patients and clinicians with rich data insights that support informed decisions in cancer care, enhancing the effectiveness of treatment options. With a strong emphasis on research and development, Presage aims to contribute to improved patient outcomes and a better understanding of cancer biology.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

5 Patents

#356 in Seattle, WA

#1,240 in Washington

#51,620 in US

Seattle, WA (US)
Seattle, WA, United States of America
Forward Citations = 7

7 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Presage Biosciences, Inc.. Retrieved from https://idiyas.com/company/presage-biosciences

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…